IL-4, IL-13, and IL-5 signaling via JAK-STAT can be therapeutically restrained in AD, while inhibition of IL-23 signaling in psoriasis can prevent transdifferentiation into pathogenic ILC subtypes (50, 53, 55). Here, IL23A is linked to psoriasis.